Charles Schwab
VYGR icon

Charles Schwab’s Voyager Therapeutics VYGR Stock Holding History

Charles Schwab’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$530K Buy
151,451
+26,338
+21% +$99.9K ﹤0.01% 3223
2026
Q1 		$483K Sell
125,113
-12,775
-9% -$50.3K ﹤0.01% 3114
2025
Q4 		$542K Sell
137,888
-4
-0% -$18 ﹤0.01% 3143
2025
Q3 		$644K Buy
137,892
+14,842
+12% +$53.7K ﹤0.01% 3089
2025
Q2 		$383K Sell
123,050
-14,521
-11% -$46.8K ﹤0.01% 3230
2025
Q1 		$465K Hold
137,571
– – ﹤0.01% 3103
2024
Q4 		$780K Buy
137,571
+94
+0.1% +$606 ﹤0.01% 2994
2024
Q3 		$804K Buy
137,477
+3,473
+3% +$25.3K ﹤0.01% 2991
2024
Q2 		$1.06M Buy
134,004
+19,552
+17% +$164K ﹤0.01% 2915
2024
Q1 		$1.07M Buy
114,452
+29,715
+35% +$251K ﹤0.01% 2779
2023
Q4 		$715K Sell
84,737
-3,436
-4% -$24.9K ﹤0.01% 2947
2023
Q3 		$683K Buy
88,173
+3,118
+4% +$28.5K ﹤0.01% 2929
2023
Q2 		$974K Buy
85,055
+72,609
+583% +$751K ﹤0.01% 2777
2023
Q1 		$96K Hold
12,446
– – ﹤0.01% 3253
2022
Q4 		$75.9K Hold
12,446
– – ﹤0.01% 3295
2022
Q3 		$74K Hold
12,446
– – ﹤0.01% 3251
2022
Q2 		$74K Sell
12,446
-3,464
-22% -$23.4K ﹤0.01% 3325
2022
Q1 		$122K Buy
+15,910
New +$71K ﹤0.01% 3388
2021
Q3 		– Sell
-114,256
Closed -$472K – 3545
2021
Q2 		$472K Sell
114,256
-50,623
-31% -$229K ﹤0.01% 3183
2021
Q1 		$777K Sell
164,879
-5,011
-3% -$34.2K ﹤0.01% 2936
2020
Q4 		$1.22M Buy
169,890
+2,663
+2% +$25.6K ﹤0.01% 2718
2020
Q3 		$1.78M Buy
167,227
+549
+0.3% +$6.44K ﹤0.01% 2527
2020
Q2 		$2.1M Sell
166,678
-39,424
-19% -$459K ﹤0.01% 2406
2020
Q1 		$1.89M Buy
206,102
+1,515
+0.7% +$17.4K ﹤0.01% 2298
2019
Q4 		$2.85M Buy
204,587
+5,299
+3% +$77K ﹤0.01% 2301
2019
Q3 		$3.43M Buy
199,288
+59,372
+42% +$1.25M ﹤0.01% 2160
2019
Q2 		$3.81M Buy
139,916
+14,647
+12% +$335K ﹤0.01% 2107
2019
Q1 		$2.4M Buy
125,269
+11,269
+10% +$147K ﹤0.01% 2302
2018
Q4 		$1.07M Sell
114,000
-1,987
-2% -$25.5K ﹤0.01% 2523
2018
Q3 		$2.19M Buy
115,987
+14,411
+14% +$277K ﹤0.01% 2403
2018
Q2 		$1.99M Buy
101,576
+14,849
+17% +$293K ﹤0.01% 2382
2018
Q1 		$1.63M Buy
86,727
+9,689
+13% +$209K ﹤0.01% 2389
2017
Q4 		$1.28M Buy
77,038
+27,250
+55% +$467K ﹤0.01% 2447
2017
Q3 		$1.03M Buy
49,788
+20,753
+71% +$234K ﹤0.01% 2504
2017
Q2 		$261K Buy
29,035
+114
+0.4% +$1.15K ﹤0.01% 2921
2017
Q1 		$383K Buy
28,921
+1,026
+4% +$12.4K ﹤0.01% 2738
2016
Q4 		$356K Buy
27,895
+924
+3% +$11.9K ﹤0.01% 2777
2016
Q3 		$324K Buy
26,971
+690
+3% +$9.34K ﹤0.01% 2762
2016
Q2 		$289K Buy
26,281
+9,010
+52% +$110K ﹤0.01% 2799
2016
Q1 		$151K Buy
17,271
+255
+1% +$2.89K ﹤0.01% 2945
2015
Q4 		$373K Buy
+17,016
New +$392K ﹤0.01% 2775

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Charles Schwab's VYGR Position: Q2 2026 in Review

Charles Schwab increased its Voyager Therapeutics (VYGR) stake by 21% in Q2 2026, buying an estimated $99.9K and bringing the position to 151,451 shares worth $530K. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Charles Schwab first reported a position in VYGR in Q4 2015 and has held it in 41 quarters since. The position peaked at $3.81M in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Charles Schwab held 151,451 shares of Voyager Therapeutics worth $530K as of Q2 2026.
  • Charles Schwab bought 26,338 Voyager Therapeutics shares in Q2 2026, an estimated $99.9K.
  • Voyager Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3223 holding.
  • Charles Schwab first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 41 quarters since.
  • Charles Schwab's Voyager Therapeutics position peaked at $3.81M in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.